leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Company profile
Ticker
CORT
Exchange
Website
CEO
Joseph Belanoff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
770487658
CORT stock data
Latest filings (excl ownership)
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 24
Transcripts
CORT
Earnings call transcript
2024 Q1
1 May 24
CORT
Earnings call transcript
2023 Q4
15 Feb 24
CORT
Earnings call transcript
2023 Q3
1 Nov 23
CORT
Earnings call transcript
2023 Q2
2 Aug 23
CORT
Earnings call transcript
2023 Q1
3 May 23
CORT
Earnings call transcript
2022 Q4
28 Feb 23
CORT
Earnings call transcript
2022 Q3
4 Nov 22
CORT
Earnings call transcript
2022 Q2
4 Aug 22
CORT
Earnings call transcript
2022 Q1
6 May 22
CORT
Earnings call transcript
2021 Q4
16 Feb 22
Latest ownership filings
4
Gary Charles Robb
30 May 24
4
William Guyer
30 May 24
4
JAMES N WILSON
28 May 24
144
Notice of proposed sale of securities
28 May 24
144
Notice of proposed sale of securities
28 May 24
4
Kimberly Park
21 May 24
4
Joshua M. Murray
21 May 24
4
Daniel N Swisher JR
21 May 24
4
Gregg H Alton
21 May 24
4
DAVID L MAHONEY
21 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 149.75 mm | 149.75 mm | 149.75 mm | 149.75 mm | 149.75 mm | 149.75 mm |
Cash burn (monthly) | (no burn) | 12.52 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 26.37 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 123.38 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 9.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
87.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 277 |
Opened positions | 247 |
Closed positions | 6 |
Increased positions | 9 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 1.81 tn |
Total shares | 91.14 mm |
Total puts | 3.24 mm |
Total calls | 2.02 mm |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 16.83 mm | $423.85 bn |
Vanguard | 9.57 mm | $240.96 bn |
Ingalls & Snyder | 8.30 mm | $209.16 mm |
Renaissance Technologies | 7.12 mm | $179.31 mm |
Parallel Advisors | 3.82 mm | $96.12 bn |
STT State Street | 3.58 mm | $90.07 bn |
Dimensional Fund Advisors | 2.57 mm | $64.68 bn |
Novo Holdings A/S | 2.41 mm | $60.74 bn |
Geode Capital Management | 2.16 mm | $54.36 bn |
First Trust Advisors | 1.84 mm | $46.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 May 24 | William Guyer | Common Stock | Sell | Dispose S | No | Yes | 32 | 30,000 | 960.00 k | 6,039 |
28 May 24 | William Guyer | Common Stock | Option exercise | Acquire M | No | No | 19.26 | 30,000 | 577.80 k | 36,039 |
28 May 24 | William Guyer | Stock option Common Stock | Option exercise | Dispose M | No | No | 19.26 | 30,000 | 577.80 k | 60,000 |
28 May 24 | Gary Charles Robb | Common Stock | Sell | Dispose S | No | Yes | 30.3904 | 11,000 | 334.29 k | 20,203 |
28 May 24 | Gary Charles Robb | Common Stock | Option exercise | Acquire M | No | No | 3.29 | 11,000 | 36.19 k | 31,203 |
28 May 24 | Gary Charles Robb | Stock option Common Stock | Option exercise | Dispose M | No | No | 3.29 | 11,000 | 36.19 k | 50,037 |
23 May 24 | Wilson James N | Common Stock | Gift | Dispose G | Yes | No | 0 | 2,000 | 0.00 | 1,314,026 |
17 May 24 | Wilson James N | Employee stock option Common Stock | Grant | Acquire A | No | No | 28.09 | 80,000 | 2.25 mm | 80,000 |
17 May 24 | G Leonard Baker JR | Stock Option Common Stock | Grant | Acquire A | No | No | 28.09 | 30,000 | 842.70 k | 30,000 |
News
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
29 May 24
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $40 Price Target
29 May 24
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
28 May 24
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
28 May 24
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
28 May 24